Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

ClinicalTrials.gov ID: NCT01529112

Public ClinicalTrials.gov record NCT01529112. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens

Study identification

NCT ID
NCT01529112
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eisai Inc.
Industry
Enrollment
135 participants

Conditions and interventions

Interventions

  • Lenvatinib Drug
  • Lenvatinib matched placebo Drug
  • BSC Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2011
Primary completion
Jan 20, 2014
Completion
Jun 26, 2015
Last update posted
Sep 25, 2017

2011 – 2015

United States locations

U.S. sites
11
U.S. states
7
U.S. cities
11
Facility City State ZIP Site status
Donald W. Hill, M.D., F.A.C.P. Casa Grande Arizona 85122
Arizona Oncology Associates , PC - HOPE Tucson Arizona 85710
Ronald Yanagihara, MD 9360 North Name Uno Suite 130 Gilroy California 95020 Gilroy California 95020
Ocala Oncology Center, P.L. Ocala Florida 34471
Washington University 660 South Euclid Avenue Campus Box 8124 St Louis Missouri 63110 St Louis Missouri 63110
New York Oncology Heamatology - Latham Clifton Park New York 12065
Montefiore Medical Park 1695 Easchester Road Floor 1 Bronx, NY 10461 New York New York 10467
Cancer Treatment and Research Centre Bismarck North Dakota 58501 Bismarck North Dakota 58501
Texas Oncology, P.A. - Paris Paris Texas 75460
Texas Oncology, P.A. - Plano Plano Texas 75093
Texas Oncology, P.A. - Waco Waco Texas 76712

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01529112, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 25, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01529112 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →